Market closed
SCYNEXIS/$SCYX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About SCYNEXIS
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Ticker
$SCYX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
29
Website
SCYNEXIS Metrics
BasicAdvanced
$45M
Market cap
-
P/E ratio
-$0.78
EPS
1.50
Beta
-
Dividend rate
Price and volume
Market cap
$45M
Beta
1.5
52-week high
$3.07
52-week low
$1.15
Average daily volume
167K
Financial strength
Current ratio
3.129
Quick ratio
3.052
Long term debt to equity
3.902
Total debt to equity
27.163
Interest coverage (TTM)
-21.35%
Management effectiveness
Return on assets (TTM)
-26.72%
Return on equity (TTM)
-48.42%
Valuation
Price to revenue (TTM)
6.713
Price to book
0.77
Price to tangible book (TTM)
0.77
Price to free cash flow (TTM)
-2.633
Growth
Revenue change (TTM)
-93.70%
Earnings per share change (TTM)
-151.84%
3-year revenue growth (CAGR)
-11.99%
3-year earnings per share growth (CAGR)
-33.03%
What the Analysts think about SCYNEXIS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for SCYNEXIS stock.
SCYNEXIS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SCYNEXIS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SCYNEXIS News
AllArticlesVideos
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·2 weeks ago
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
GlobeNewsWire·1 month ago
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for SCYNEXIS stock?
SCYNEXIS (SCYX) has a market cap of $45M as of November 23, 2024.
What is the P/E ratio for SCYNEXIS stock?
The price to earnings (P/E) ratio for SCYNEXIS (SCYX) stock is 0 as of November 23, 2024.
Does SCYNEXIS stock pay dividends?
No, SCYNEXIS (SCYX) stock does not pay dividends to its shareholders as of November 23, 2024.
When is the next SCYNEXIS dividend payment date?
SCYNEXIS (SCYX) stock does not pay dividends to its shareholders.
What is the beta indicator for SCYNEXIS?
SCYNEXIS (SCYX) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.